RV - Right Ventricular AbnormalityNCT06739057
Pediatric Ventricle Function Assessment Study
An observational study of RV - Right Ventricular Abnormality and LV Dysfunction, run by HBI Solutions Inc. at 1 site in United States.
Trial summary
This study aims to develop a deep learning-based framework for right ventricular (RV) segmentation, prediction of RV fractional area change (FAC), and identification of pediatric RV dysfunction. Read more about this study
- Who is it for?
- Ages Up to 18 yearsHealthy volunteers can take part
- Conditions the study is for
- RV - Right Ventricular Abnormality, LV Dysfunction, Pulmonary Hypertension
- How many people
- 3,993 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Jan 2014to 31 Aug 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 18 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Study population: Two groups of children are included. Group I: Children with normal right ventricular anatomy and function assessment based on screening echocardiograms and physcian follow up. Group II: Children with right ventricular abnormalities who have potential risk of adverse outcomes.
Who may be able to join
- Patients aged 0-18 years old.
- Patients with the following diagnoses (defined as abnormal RVs): premature infants with lung disease, congenital heart disease with systemic right ventricles, surgically repaired congenital heart disease resulting in pressure and/or volume load on the RV (tetralogy of Fallot, Double outlet right ventricle, etc.), and idiopathic pulmonary hypertension.
Who cannot join
- -
Trial locations and contacts
1 site in 1 country.
About this study
This study aims to develop a deep learning-based framework for right ventricular (RV) segmentation, prediction of RV fractional area change (FAC), and identification of pediatric RV dysfunction. The AI model was designed to distinguish between normal pediatric hearts, pulmonary hypertension (PH), and Tetralogy of Fallot (TOF). To improve diagnostic accuracy, the investigators extended the analysis beyond the A4C view by integrating data from both A4C and PSAX views. Additionally, the framework was applied to predict left ventricular ejection fraction (LV EF), further showcasing its versatility and clinical utility.
Read the detailed description
Heart defects are a leading cause of birth defect-associated illness and mortality worldwide, affecting approximately 1% of live births globally. Among these, about one-quarter1 present with critical heart defects requiring early intervention to improve survival and outcomes.Right ventricular (RV) dysfunction is a prevalent form of heart disease in pediatric patients, often arising from conditions such as prematurity, post-surgical effects of congenital heart disease, functioning as the systemic ventricle, and idiopathic pulmonary hypertension. These patients face significant risks, including RV failure, decreased quality of life, potential need for transplantation, and increased mortality. Accurate assessment of RV function is crucial but challenging due to the RV's complex geometry.
Unlike left ventricular (LV) dysfunction, RV dysfunction primarily results from pressure and volume overloads and has unique pathophysiological characteristics. While LV dysfunction mechanisms are well-studied, less is known about RV, and much of its clinical management is adapted from LV-focused research. The RV, with its thinner and more adaptable walls, remodels efficiently but often tolerate changes for extended periods before failure. Furthermore, RV dysfunction frequently leads to LV dysfunction due to strong interventricular interactions. These differences, along with the RV's irregular shape and orientation, complicate imaging and assessment, requiring advanced imaging techniques, often involving multiple modalities.
Precise evaluation of RV size and function is essential for diagnosing, managing, and predicting outcomes in pediatric cardiac conditions. Echocardiography, as a non-invasive and accessible tool, is the first-line imaging technique for monitoring RV function). However, traditional RV functional measures face limitations in pediatric populations due to significant variability in RV morphology. Among systolic parameters, fractional area change (FAC) has demonstrated stronger correlations with disease severity in advanced heart failure patients and a closer relationship with RV ejection fraction as measured by cardiovascular magnetic resonance (CMR), suggesting its reliability in assessing pediatric RV function. An FAC <35% is considered abnormal by the guideline. Accurate FAC assessment can guide timely interventions, improve prognosis, and enhance long-term outcomes by enabling better monitoring of RV function over time.
Congenital Heart Disease (CHD) includes a wide range of structural abnormalities and conditions that affect the heart's development before birth, with examples such as Tetralogy of Fallot (TOF) and Pulmonary hypertension(PH). The RV plays a crucial role in TOF diagnosis because its outflow tract obstruction and hypertrophy are primary features of the condition. Pulmonary hypertension increases the afterload (pressure) on the right ventricle, leading to RV structural and functional changes. These changes are typically not seen in the LV unless there is severe biventricular involvement or secondary effects.
Echocardiography is a non-invasive, widely accessible, and essential first-line tool for routine follow-up of various pediatric cardiac conditions affecting the right ventricle (RV). However, assessing RV function in pediatric heart disease remains challenging due to significant variability in RV morphology and physiology. The apical four-chamber (A4C) view is a cornerstone for right ventricular (RV) function assessment due to its ability to evaluate RV size, shape, and systolic function comprehensively. The parasternal short-axis (PSAX) view is often used as a supplementary echocardiographic view alongside the A4C view for assessing right ventricular (RV) function. Advances in AI-driven echocardiography, particularly deep learning, hold promise for enhancing cardiac function assessment. Recent innovations, like EchoNet-Dynamic, have shown the utility of video-based deep learning algorithms for adult LV segmentation and ejection fraction estimation. Building on this progress, the investigators developed EchoNet-Peds , an AI model for pediatric echocardiography that automates LV segmentation and ejection fraction calculations. Beside left ventricle segmentation methods, other deep learning applications include automated quantification of left ventricular structure and function, as well as novel methods for estimating intraventricular hemodynamic parameters on a beat-to-beat basis . However, most deep learning studies focus on LV assessment, with comparatively fewer models dedicated to the RV, mainly addressing segmentation tasks. While some recent advancements have emerged, such as a model estimating RV ejection fraction from echocardiographic images in pulmonary arterial hypertension patients , significant gaps remain in applying AI to pediatric RV functional assessment.
This study aims to develop a deep learning-based framework for right ventricular (RV) segmentation, prediction of RV fractional area change (FAC), and identification of pediatric RV dysfunction. The AI model was designed to distinguish between normal pediatric hearts, pulmonary hypertension (PH), and Tetralogy of Fallot (TOF). To improve diagnostic accuracy, the investigators extended the analysis beyond the A4C view by integrating data from both A4C and PSAX views. Additionally, the framework was applied to predict left ventricular ejection fraction (LV EF), further showcasing its versatility and clinical utility.
- Keywords
- Echocardiogram, Right Ventricle (RV), Pulmonary Hypertension, TOF
- Medical subject headings
- Ventricular Dysfunction, Left, Hypertension, Pulmonary
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| RV FAC Prediction Cohort | This cohort is designed to predict pediatric RV FAC using a deep learning model based on echocardiograms | |
| RV Disease Classification Cohort | The cohort is designed to employ a deep learning model to differentiate between normal pediatric hearts and pulmonary hypertension (PH), as well as between Tetralogy of Fallot (TOF) and PH, using echocardiograms. | |
| RV Function Assessment and Disease Classification Using A4C and PSAX View Cohorts | The cohort is designed to utilize A4C and PSAX echocardiographic views for pediatric RV function assessment and disease classification using deep learning models. | |
| LV Ejection Fraction (EF) Prediction Cohort | The cohort is designed to validate our new deep learning model for LV EF assessment. |
What is being measured
The primary outcome is the main question the study is designed to answer.
RV dysfunction prediction
FAC < 35% is considered RV abnormal. The automated extracted FAC values were then used to predict the probability of abnormal RV function.FAC estimation accuracy was evaluated using mean absolute error (MAE), root mean squared error (RMSE), and Pearson correlation coefficient (R). Diagnostic performance metrics included AUC, sensitivity, and specificity for RV function assessment
Measured: 10 minutes
Congenital Heart Disease Detection
For CHD detection, classification models were developed to distinguish between normal, PH, and TOF cases by analyzing RV echocardiogram videos. Accuracy, sensitivity, and specificity were used to evaluate the classifications of PH versus normal and PH versus TOF
Measured: 10 minutes
Left Ventricle Dysfunction
The performance is assessed by calculating the area under the receiver operating characteristic (ROC) curve , evaluating the model's accuracy in detecting abnormal EF values.
Measured: 10 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Dec 2024
- Study start1 Jan 2014
- Primary completion31 Aug 2024
- Study completion31 Aug 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for RV - Right Ventricular AbnormalityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 3,993 participants (actual)
Sponsor and investigators
- Lead sponsor
- HBI Solutions Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Principal investigator, Doff McElhinney, HBI Solutions Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06739057
- Sponsor's protocol ID
- ECHO_1
- Status last verified
- Dec 2024
- First submitted
- 12 Dec 2024
- Last updated
- 20 Dec 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Dec 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pediatric Ventricle Function Assessment Study
- ClinicalTrials.gov ID
- NCT06739057
- Acronym / sponsor ID
- ECHO_1
- Keywords
- Echocardiogram, Right Ventricle (RV), Pulmonary Hypertension, TOF
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 3,993 participants (actual)
- Lead sponsor
- HBI Solutions Inc.Industry (pharma, biotech, devices)
- Study start
- 1 Jan 2014 (actual)
- Primary completion
- 31 Aug 2024 (actual)
- Study completion
- 31 Aug 2024 (actual)
- First posted
- 18 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to develop a deep learning-based framework for right ventricular (RV) segmentation, prediction of RV fractional area change (FAC), and identification of pediatric RV dysfunction. The AI model was designed to distinguish between normal pediatric hearts, pulmonary hypertension (PH), and Tetralogy of Fallot (TOF). To improve diagnostic accuracy, the investigators extended the analysis beyond the A4C view by integrating data from both A4C and PSAX views. Additionally, the framework was applied to predict left ventricular ejection fraction (LV EF), further showcasing its versatility and clinical utility.
Detailed description
Heart defects are a leading cause of birth defect-associated illness and mortality worldwide, affecting approximately 1% of live births globally. Among these, about one-quarter1 present with critical heart defects requiring early intervention to improve survival and outcomes.Right ventricular (RV) dysfunction is a prevalent form of heart disease in pediatric patients, often arising from conditions such as prematurity, post-surgical effects of congenital heart disease, functioning as the systemic ventricle, and idiopathic pulmonary hypertension. These patients face significant risks, including RV failure, decreased quality of life, potential need for transplantation, and increased mortality. Accurate assessment of RV function is crucial but challenging due to the RV's complex geometry.
Unlike left ventricular (LV) dysfunction, RV dysfunction primarily results from pressure and volume overloads and has unique pathophysiological characteristics. While LV dysfunction mechanisms are well-studied, less is known about RV, and much of its clinical management is adapted from LV-focused research. The RV, with its thinner and more adaptable walls, remodels efficiently but often tolerate changes for extended periods before failure. Furthermore, RV dysfunction frequently leads to LV dysfunction due to strong interventricular interactions. These differences, along with the RV's irregular shape and orientation, complicate imaging and assessment, requiring advanced imaging techniques, often involving multiple modalities.
Precise evaluation of RV size and function is essential for diagnosing, managing, and predicting outcomes in pediatric cardiac conditions. Echocardiography, as a non-invasive and accessible tool, is the first-line imaging technique for monitoring RV function). However, traditional RV functional measures face limitations in pediatric populations due to significant variability in RV morphology. Among systolic parameters, fractional area change (FAC) has demonstrated stronger correlations with disease severity in advanced heart failure patients and a closer relationship with RV ejection fraction as measured by cardiovascular magnetic resonance (CMR), suggesting its reliability in assessing pediatric RV function. An FAC <35% is considered abnormal by the guideline. Accurate FAC assessment can guide timely interventions, improve prognosis, and enhance long-term outcomes by enabling better monitoring of RV function over time.
Congenital Heart Disease (CHD) includes a wide range of structural abnormalities and conditions that affect the heart's development before birth, with examples such as Tetralogy of Fallot (TOF) and Pulmonary hypertension(PH). The RV plays a crucial role in TOF diagnosis because its outflow tract obstruction and hypertrophy are primary features of the condition. Pulmonary hypertension increases the afterload (pressure) on the right ventricle, leading to RV structural and functional changes. These changes are typically not seen in the LV unless there is severe biventricular involvement or secondary effects.
Echocardiography is a non-invasive, widely accessible, and essential first-line tool for routine follow-up of various pediatric cardiac conditions affecting the right ventricle (RV). However, assessing RV function in pediatric heart disease remains challenging due to significant variability in RV morphology and physiology. The apical four-chamber (A4C) view is a cornerstone for right ventricular (RV) function assessment due to its ability to evaluate RV size, shape, and systolic function comprehensively. The parasternal short-axis (PSAX) view is often used as a supplementary echocardiographic view alongside the A4C view for assessing right ventricular (RV) function. Advances in AI-driven echocardiography, particularly deep learning, hold promise for enhancing cardiac function assessment. Recent innovations, like EchoNet-Dynamic, have shown the utility of video-based deep learning algorithms for adult LV segmentation and ejection fraction estimation. Building on this progress, the investigators developed EchoNet-Peds , an AI model for pediatric echocardiography that automates LV segmentation and ejection fraction calculations. Beside left ventricle segmentation methods, other deep learning applications include automated quantification of left ventricular structure and function, as well as novel methods for estimating intraventricular hemodynamic parameters on a beat-to-beat basis . However, most deep learning studies focus on LV assessment, with comparatively fewer models dedicated to the RV, mainly addressing segmentation tasks. While some recent advancements have emerged, such as a model estimating RV ejection fraction from echocardiographic images in pulmonary arterial hypertension patients , significant gaps remain in applying AI to pediatric RV functional assessment.
This study aims to develop a deep learning-based framework for right ventricular (RV) segmentation, prediction of RV fractional area change (FAC), and identification of pediatric RV dysfunction. The AI model was designed to distinguish between normal pediatric hearts, pulmonary hypertension (PH), and Tetralogy of Fallot (TOF). To improve diagnostic accuracy, the investigators extended the analysis beyond the A4C view by integrating data from both A4C and PSAX views. Additionally, the framework was applied to predict left ventricular ejection fraction (LV EF), further showcasing its versatility and clinical utility.
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| RV FAC Prediction Cohort | – | –This cohort is designed to predict pediatric RV FAC using a deep learning model based on echocardiograms |
| RV Disease Classification Cohort | – | –The cohort is designed to employ a deep learning model to differentiate between normal pediatric hearts and pulmonary hypertension (PH), as well as between Tetralogy of Fallot (TOF) and PH, using echocardiograms. |
| RV Function Assessment and Disease Classification Using A4C and PSAX View Cohorts | – | –The cohort is designed to utilize A4C and PSAX echocardiographic views for pediatric RV function assessment and disease classification using deep learning models. |
| LV Ejection Fraction (EF) Prediction Cohort | – | –The cohort is designed to validate our new deep learning model for LV EF assessment. |
Who may qualify
- Ages
- Up to 18 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
- Study population
- Two groups of children are included. Group I: Children with normal right ventricular anatomy and function assessment based on screening echocardiograms and physcian follow up. Group II: Children with right ventricular abnormalities who have potential risk of adverse outcomes.
Key inclusion criteria (2 listed)
- Patients aged 0-18 years old.
- Patients with the following diagnoses (defined as abnormal RVs): premature infants with lung disease, congenital heart disease with systemic right ventricles, surgically repaired congenital heart disease resulting in pressure and/or volume load on the RV (tetralogy of Fallot, Double outlet right ventricle, etc.), and idiopathic pulmonary hypertension.
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
RV dysfunction prediction
Time frame: 10 minutes
FAC < 35% is considered RV abnormal. The automated extracted FAC values were then used to predict the probability of abnormal RV function.FAC estimation accuracy was evaluated using mean absolute error (MAE), root mean squared error (RMSE), and Pearson correlation coefficient (R). Diagnostic performance metrics included AUC, sensitivity, and specificity for RV function assessment
Congenital Heart Disease Detection
Time frame: 10 minutes
For CHD detection, classification models were developed to distinguish between normal, PH, and TOF cases by analyzing RV echocardiogram videos. Accuracy, sensitivity, and specificity were used to evaluate the classifications of PH versus normal and PH versus TOF
Left Ventricle Dysfunction
Time frame: 10 minutes
The performance is assessed by calculating the area under the receiver operating characteristic (ROC) curve , evaluating the model's accuracy in detecting abnormal EF values.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Dec 2024.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of RV - Right Ventricular Abnormality and LV Dysfunction, run by HBI Solutions Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
RV dysfunction prediction (time frame: 10 minutes). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Dec 2024.